Sartorius and NVIDIA to Develop AI Models for Stem Cell-Derived Organoids, Reducing Animal Testing in Drug Discovery

by Roman Kasianov       News

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

   371    Comments 0
Topics: Emerging Technologies   
Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email   |  

Sartorius, a leader in life sciences and bioprocessing, is expanding its collaboration with NVIDIA to enhance the development of innovative therapies. A key focus of this collaboration is the development of predictive AI models for stem cell-derived organoids, which are intended to replace animal models in drug discovery and precision medicine.

Sartorius has utilized NVIDIA’s technology since 2020, incorporating it into its live-cell imaging platforms. This integration supports edge computing applications and enables AI-driven assays for laboratory use. One key area of focus has been the development of predictive AI models for stem cell-derived organoids, which are poised to replace animal models in drug discovery and precision medicine. Additionally, Sartorius employs NVIDIA’s solutions for designing and simulating bioprocesses critical to manufacturing novel therapies.

See also: A Landscape of AI-discovered Molecules and Target Novelty Analysis

The expanded collaboration will see an increased use of the NVIDIA Clara suite—an AI-powered suite of computing platforms, software, and services—within the Sartorius ecosystem. Sartorius plans to develop and commercialize foundational models based on its unique and extensive datasets. These models, along with new predictive AI tools and simulations, will be made accessible to Sartorius customers via the NVIDIA Clara suite and the NVIDIA DGX platform.

Looking ahead, Sartorius and NVIDIA will explore a range of advanced technologies. These include the computer-based design and simulation of complex 3D-bioprinted spheroids and organoids, as well as synthetic biological pathways and organisms engineered from Sartorius cell lines. These innovations aim to produce new therapeutic agents and therapies, reflecting a forward-thinking approach to technology integration in the biopharmaceutical sector.

This collaboration also involves ongoing dialogue with regulatory authorities to address the application of AI in life sciences, ensuring that these technological advancements meet regulatory standards and can be effectively implemented in the industry.

Topics: Emerging Technologies   

Share:   Share in LinkedIn  Share in Reddit  Share in X  Share in Hacker News  Share in Facebook  Send by email

Comments:

There are no comments yet. You can be the first.

Leave a Reply

Your email address will not be published. Required fields are marked *